Clinical Trials Details

NRG-GY023 (Ovary/Peritoneum)

A Randomized Phase II Trial of Triplet Therapy (Durvalumab (MEDI4736) in combination with Olaparib and Cediranib) compared to Olaparib and cediranib or Durvalumab (MEDI4736) and Cediranib or standard of care chemotherapy in women with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal or fallopian cancer who have received prior bevacizumab

Objective

» Learn more about this trial

Clinical Trial Categories

• Cancers and Other Neoplasms